

# Appendix 1: Membership of the BMA Board of Science Reference Group

## **Professor Sue Bailey**

*President, Royal College of Psychiatrists*

Professor Sue Bailey is a Consultant Child and Adolescent Forensic Psychiatrist at the Greater Manchester West NHS Foundation Trust, and was recently elected the President of the Royal College of Psychiatrists.

Professor Bailey was dual trained in child and adolescent psychiatry and forensic psychiatry. The focus of her clinical and research work has been on developing needs- and risk-assessment programmes, as well as evidenced-based interventions to improve outcomes for young people with complex mental health needs who present as high risk of harm to others and themselves. She has worked in specialist inpatient and community services, and has interests in human rights in practice, and mental health and social care policy in national and international contexts. Through various roles in the Royal College of Psychiatrists, Professor Bailey has worked to support stronger partnerships between users, carers and families. She has sought to increase recognition of the importance of mental health across medicine, as well as the negative impact of psychosocial adversity on the mental health of the individual, their families and local communities.

### **Declaration of interests:**

Professor Bailey declares no support from any organisation for the submitted work and

no financial relationships with any organisations that might have had an interest in the submitted work in the previous three years.

## **Dr James Bell**

*Consultant in Addictions Medicine, South London and Maudsley NHS Foundation Trust*

Dr James Bell is a physician specialising in addiction medicine. He is a consultant in addictions at South London and Maudsley NHS Foundation Trust. Dr Bell has been active in the development of training programmes for health professionals, and was a leading figure in establishing the Chapter of Addiction Medicine within the Royal Australasian College of Physicians. His major research interest is the treatment of opioid dependence but he has also recently developed a 'party drugs' clinic in South London, and has been involved in developing a new clinical pathway for management of acute alcohol withdrawal presenting to emergency departments.

### **Declaration of interests:**

Dr Bell is in receipt of research funding from Reckittbenckiser PLC, manufacturers and distributors of buprenorphine. He has been funded to attend conferences and seminars by Reckittbenckiser, Schering-Plough Corporation and Titan Pharmaceuticals.

### **Dr Owen Bowden-Jones**

*Consultant Psychiatrist, Addictions Directorate, Central and North West London NHS Foundation Trust; Chair, Faculty of Addictions, Royal College of Psychiatrists; and Honorary Senior Lecturer, Imperial College, London*

Dr Owen Bowden-Jones is a Consultant in Addiction Psychiatry at the Chelsea and Westminster Hospital and Honorary Senior Lecturer at Imperial College. He oversees three teams providing treatment for alcohol, drugs and mental health problems. Recently, Dr Bowden-Jones set up the UK's largest multidisciplinary service for people using novel psychoactive substances ('legal highs') and 'club drugs' and is developing innovative approaches to treat dependence on these substances. Dr Bowden-Jones is the Chair of the Faculty of Addictions, Royal College of Psychiatrists. In this role he sits on a number of working groups. The position also requires regular meetings with Government and other professional groups. Other responsibilities include clinical lead for a large quality improvement project for blood-borne virus treatment in west London and Chair of Medicines Management for his trust.

#### **Declaration of interests:**

Owen Bowden-Jones declares that he has no conflicts of interests.

### **Ms Amanda Feilding**

*Director, The Beckley Foundation*

Ms Amanda Feilding established the Beckley Foundation in 1998 to help reform national and global drug policy by creating evidence-based, health-orientated, harm-reducing, cost-effective drug policies that recognise human rights. The Foundation has organised nine influential international drug policy seminars, hosted mainly at the House of Lords, and has commissioned over 35 books, drug policy reports and proceedings documents, including *Cannabis policy: moving beyond stalemate*. The Foundation has also recently commissioned two important reports: (1) *Roadmap to reforming the UN drug conventions*, which describes possible amendments to the United Nations drugs conventions that would give individual signatory countries more freedom to experiment with alternative drug policies; and (2) *A cost/benefit analysis of a regulated and taxed cannabis market in England and Wales*. The Beckley Foundation Scientific Programme investigates the neurophysiology and psychopharmacology of cannabis, psilocybin, MDMA (ecstasy), LSD (lysergic acid diethylamide) and novel psychoactive substances ('legal highs'), to better understand how these compounds work, and identify potential therapeutic applications, as well as to inform policy.

#### **Declaration of interests:**

Amanda Feilding declares that she has no conflicts of interests.

### **Dr Emily Finch**

*Clinical Director, Addictions Clinical Academic Group, South London and Maudsley Foundation NHS Trust*

Dr Emily Finch is a Consultant Addiction Psychiatrist working for the South London and Maudsley NHS Foundation Trust. Emily is Clinical Director for the Addictions Clinical Academic Group, with responsibility for addiction services across Lambeth, Southwark, Bexley, Greenwich and Croydon, and inpatient services based at the Maudsley Hospital. From 2004 to 2007, Emily was the Clinical Team Leader at the National Treatment Agency, where she took a lead in the clinical aspects of national drug policy and in liaising between the National Treatment Agency and the professionals working in the field. She was part of the secretariat for the 2007 joint publication of the Department of Health (England), the Scottish Government, the Welsh Assembly Government and the Northern Ireland Executive, *Drug misuse and dependence: guidelines on clinical management*, and a member of the guideline development group for the National Institute for Health and Clinical Excellence guideline on opiate detoxification. Emily is also a member of the Addictions Executive of the Royal College of Psychiatrists. Emily is a tutor, lecturer and examiner on the MSc in Clinical and Public Health Aspects of Addiction, and is an experienced expert witness in family and criminal cases. Emily is a Trustee of Phoenix Futures. Emily is currently Chair for the National Institute for Health and Clinical Excellence Drug Use Disorders Quality Standard Topic Expert Group.

#### **Declaration of interests:**

Emily Finch declares no support from any organisation for the submitted work and no financial relationships with any organisations that might have had an interest in the submitted work in the previous three years.

### **Professor Sir Ian Gilmore**

*Immediate Past President, Royal College of Physicians*

Professor Sir Ian Gilmore is a Professor of Medicine at the University of Liverpool and was a consultant physician at the Royal Liverpool University Hospitals until April 2011. His specialty interest is liver disease. He is the immediate past president of the Royal College of Physicians and is president-elect of the British Society of Gastroenterology. He has particular interest in harms related to alcohol misuse and the role of regulation in reducing this. He chaired a Royal College of Physicians Working Party in 2001, producing the report *Alcohol – can the NHS afford it? A blueprint for a coherent alcohol strategy*. He chairs the UK Alcohol Health Alliance, in which relevant agencies work together in a coherent and focused framework. He has also been appointed as Chair of the European Alcohol and Health Forum Science Group and chairs the global science group of a European Commission cofunded multimillion Euro project on reframing addiction. He is a member of the Climate and Health Council and of the National Quality Board. He received a Knighthood in the Queen's Birthday Honours in 2010.

#### **Declaration of interests:**

Sir Ian is a trustee of Alcohol Research (UK) and of the British Society of Gastroenterology. He is Chair of the Alcohol

Health Alliance UK, Liverpool Health Partners, and the Global Science Group of ALICE-RAP, a European Commission cofunded project on reframing addiction in Europe. Sir Ian is also a Special Adviser on Alcohol and Public Health to the Royal College of Physicians.

### **Ms Arsha Gosine**

*Policy Adviser, Crown Prosecution Service*

Arsha is a Policy Adviser with the Crown Prosecution Service and is their policy lead for drugs. Arsha holds a Masters in International Law and has presented on criminal law issues in the UK and abroad. For the last four years Arsha has acquired an expertise in drug-related offences and provides legal guidance and updates for prosecutors nationally. Arsha is a member of the Association of Chief Police Officers Drugs Committee.

#### **Declaration of interests:**

Arsha Gosine has no competing interests that might be perceived as posing a conflict or bias.

### **Mr Nicholas Green QC**

*Barrister, Brick Court Chambers*

Nicholas Green is a barrister specialising in all aspects of competition, European, regulatory and administrative law. He appears before all levels of the domestic English courts and appears regularly in international courts and tribunals. In 2010 he was the Chairman of the Bar Council of England and Wales. In his capacity as Chairman of the Bar he was involved in leading negotiations with Government on behalf of the profession on all issues from reform of criminal and civil justice systems to legal aid reform. He represented the profession internationally at conferences and in bilateral negotiations and discussions with foreign Bars and Governments. Prior to becoming Chairman he had been a member of the Bar Council for nearly 10 years. He has subsequently been appointed as the Chairman of the Advocacy Training Council, a body that facilitates and coordinates the training of and professional support for the Bar. He has held a long-term interest in the impact of drugs policy upon the administration of the justice system. He sits as a Recorder in the Crown Court. He is also joint Head of Chambers at Brick Court Chambers in London.

#### **Declaration of interests:**

Nicholas Green has no interests that conflict or compete with the issues being considered in the report and that would affect his views.

### **Mr Tim Hollis CBE**

*Chief Constable of Humberside; Vice President, Association of Chief Police Officers; and Chair, Association of Chief Police Officers Drugs Committee*

After attending Bristol University and undertaking a short service commission in the Parachute Regiment, Tim Hollis joined the Metropolitan Police in 1977. He subsequently served in Sussex Police and as a Chief Officer in South Yorkshire Police, during which time he also held national responsibilities for public order policing. In 2002, he moved to Her Majesty's Inspectorate of Constabulary prior to becoming Chief Constable of Humberside Police in 2005. He leads nationally on drugs and is one of the Vice Presidents of Association of Chief Police Officers. He was awarded the QPM (Queen's Police Medal) in January 2000 and CBE (Commander of the British Empire) in January 2010.

#### **Declaration of interests:**

Tim Hollis declares no support from any organisation for the submitted work and no financial relationships with any organisations that might have an interest in the submitted work in the previous three years.

### **Baroness Molly Meacher**

*Chair, Parliamentary International Drugs Policy Reform Group; Chair, East London NHS Foundation Trust; and House of Lords*

Baroness Molly Meacher is the Chair of the All Party Parliamentary Group on Drug Policy Reform. She is also the Chair of East London NHS Foundation Trust and a crossbench member of the House of Lords. Formerly she has been the Chairman of the Security Industry Authority and Deputy Chairman of the Police Complaints Authority. In the 1990s, Molly worked in Russia for four years, advising the Russian Government on the development of a system to handle unemployment. She is the author or editor of a number of books on the benefits system, mental health and the tax system. She was actively involved in the development of the 1983 Mental Health Act and spent five years as a Mental Health Act Commissioner. Her political interests include mental health, criminal justice, welfare benefits and social care.

#### **Declaration of interests:**

Baroness Meacher declares no support from any organisation for the submitted work and no financial relationships with any organisations that might have had an interest in the submitted work in the previous three years.

### **Dr David Pickersgill**

*Immediate past Treasurer,  
British Medical Association*

Dr Pickersgill was Treasurer of the BMA from 2002 to 2011. He is a long-serving member of BMA Council and has served on many other BMA committees, including its Private Practice and Forensic Medicine Committees, both of which he previously chaired.

David was a GP in North Norfolk for 30 years, running a market town dispensing practice. For approximately half of that time he was a local police surgeon.

#### **Declaration of interests:**

David Pickersgill declares that he has no conflicts of interests.

### **Dr Kylie Reed**

*Honorary SpR and Research Worker,  
National Addiction Centre, Institute  
of Psychiatry, King's College London,  
and South London and Maudsley  
Foundation NHS Trust*

Dr Kylie Reed is an Addiction Psychiatrist working for the National Addiction Centre, Institute of Psychiatry, and South London and Maudsley NHS Foundation Trust. Kylie has worked in clinically diverse settings in addiction psychiatry, including inpatient units and the smoking cessation service at the Maudsley Hospital, community treatment centres, a homelessness hostel, and a clinic prescribing injectable opiates as second-line treatment. From 2008 to 2009, Kylie worked as an adviser in the Substance Misuse Policy team at the Department of Health. Kylie tutors, lectures and is an internal examiner on the MSc in Clinical and Public Health Aspects of Addiction, at King's College London. She completed her MA in clinical sciences at St John's College,

Cambridge, and her degree in medicine (BMBCh) at Oxford University. She trained in psychiatry at the Maudsley and Bethlem Royal Hospitals and Southampton University Hospital. Her clinical and research interests include dual diagnosis, the healthcare of opiate users, dependence on prescribed medications, smoking cessation and homelessness healthcare.

#### **Declaration of interests:**

Kylie Reed coordinated a Department of Health-funded review of published English and international evidence and available data to inform consideration of the extent of dependence on and harm from prescribed benzodiazepines and z-drugs and of over-the-counter codeine-containing products in England. Kylie has received support from Schering-Plough to attend a conference on new advances in opiate addiction treatment, and has received honoraria for two small reviews for a market research company that works with Acetelion, a pharmaceutical company that does not currently produce any medicines for use in the addiction treatment field. In the past, Kylie has been seconded to work at the Department of Health, and has worked with the World Health Organisation, the General Medical Council and currently works with National Institute for Health and Clinical Excellence. Kylie Reed has worked in the field of addiction psychiatry since 2006.

### **Mr Stephen Rolles**

*Senior Policy Analyst, Transform Drug Policy Foundation*

Steve is Senior Policy Analyst for Transform Drug Policy Foundation, where he has worked since 1998. Transform is a UK-based drug policy think tank and registered charity working in the field of drug policy and law reform. As well as publications in journals, periodicals and book chapters, Steve has been lead author on a range of Transform publications including *After the war on drugs: blueprint for regulation* (2009). Steve has been a regular contributor to the public debate on drug policy and law: in print and broadcast media, as a speaker at UK and international conferences/events, and at various UN, UK Government and Parliamentary Select Committee hearings and inquiries. Before Transform, Steve worked for the Medical Research Council and Oxfam, having studied Geography at Bristol University (BSc) and Development Studies at Manchester University (MA).

#### **Declaration of interests:**

Transform Drug Policy Foundation is a charitable think tank. Its purpose is to draw public attention to their opinion that drug prohibition itself is the major cause of drug-related harm to individuals, communities and nations. Transform campaigns for drug prohibition to be replaced by effective, just and humane Government control and regulation.

### **Professor John Strang**

*Professor of the Addictions and Director, Addiction Research Unit, Institute of Psychiatry, Kings College London*

Professor John Strang is the Head of the Addictions Department at King's College London and has been a Consultant Psychiatrist in addictions treatment for over 30 years, first in Manchester and subsequently at the South London and Maudsley NHS Foundation Trust. He has had extensive experience in charge of a wide range of treatments in community and residential settings. His area of particular clinical expertise is heroin addiction. Professor Strang completed his undergraduate medical (MBBS) and postgraduate psychiatry studies at Guy's Hospital, London. He trained in psychiatry at the Maudsley/Bethlem Royal Hospital between 1976 and 1982. In 1995, he was awarded a thesis-based higher degree (MD) at the University of London. Research interests include: supervised injecting clinics for managing entrenched heroin addicts who cannot otherwise be engaged in treatment; new approaches to preventing drug-overdose deaths, involving family members; and contingency management to improve treatments to reduce drug use and associated harms. He has made contributions to the Department of Health, Home Office, Royal College of Psychiatrists, BMA, General Medical Council, General Dental Council, Royal Pharmaceutical Society, National Treatment Agency, World Health Organisation and United Nations, and has published over 400 papers.

**Declaration of interests:**

Professor Strang declares that he has worked with UK and international Government agencies on treatment guidelines, including chairing UK Department of Health and National Institute for Health and Clinical Excellence clinical guidelines committees; has contributed to the work of organisations that review evidence of effectiveness of drug policy; has received research and educational grant support or honoraria, consultancy payments, and travelling, accommodation, or conference expenses from pharmaceutical companies that produce, or have been considering producing, new medicines or new formulations for use in the addiction treatment field, including (past 3 years) – Genus (Britannia), Viropharma (Auralis), Martindale (Catalent), Reckitt-Benckiser, Schering-Plough, Lundbeck, UCB, Napp (MundiPharma), Lightlake, and Fidelity International. He works within an integrated university and NHS academic health sciences centre (Kings Health Partners AHSC) and is supported by the National Institute for Health Research Biomedical Research Centre for Mental Health at the Institute of Psychiatry, Kings College London and South London and Maudsley NHS Foundation Trust, which provides treatments and undertakes research study; and has close links with various other treatment provider organisations.

**Mr John Witton**

*Researcher, King's College London*

John Witton is a researcher at the Addictions Department at King's College London and previously worked in the Library and Information Service of the Institute for the Study of Drug Dependence (now DrugScope) 1977-1997. He has received project grant support and/or honoraria and/or consultancy payments from the Department of Health, National Treatment Agency, Home Office, European Monitoring Centre for Drugs and Drug Addiction and United Nations Office on Drugs and Crime. He is on the management board of Drug and Alcohol Findings and a trustee of Bromley Mind.

**Declaration of interests:**

John Witton declares that he has received no support from any organisation for the submitted work and no financial relationships with any organisations that might have had an interest in the submitted work in the previous three years.

**Professor Jonathan Wolff**

*Professor of Philosophy and Director of the Centre for Philosophy, Justice and Health, University College London*

Professor Wolff's work has largely concentrated on issues of distributive justice, with a particular interest in the relation between theory and policy. Recently, he has worked on topics such as disadvantage, disability, risk and the measurement of health, and was principal investigator on the Arts and Humanities Research Council funded project, *The Ethics of Risk*. He is a member of the Nuffield Council on Bioethics, and the Ethics Committee of the Royal College of Obstetrics and Gynaecology. Formerly, he was a member of the Gambling Review Body, the Nuffield Council Working Party on the Ethics of Research Involving Animals, and the Academy of Medical Sciences Working Party on Brain Science and Addiction. He is currently advising an interdepartmental government committee on the valuation of life and health. His recent books include *Ethics and public policy: a philosophical inquiry* (2011) and *The human right to health* (2012).

**Declaration of interests:**

Professor Wolff declares that he has worked with the Academy of Medical Sciences and the Nuffield Council of Bioethics on issues related to the topic of this report, and has received research and educational grant support or honoraria, consultancy payments, and travelling, accommodation, or conference expenses from Pfizer UK Ltd and Merck Sharp and Dunne. He has had no support from any organisation for the submitted work and, other than the above, no financial relationships with any organisations that might have had an interest in the submitted work in the previous three years.

